Exagen Inc. (XGN) Revenue History
Annual and quarterly revenue from 2012 to present
XGN Revenue Over Time (2012–2025)
XGN Revenue Growth History
11 of 12 years with positive growth- FY2012 revenue growth
- N/A
- FY2013 revenue growth
- +229.9%
- FY2014 revenue growth
- +281.8%
- FY2015 revenue growth
- +53.9%
- FY2017 revenue growth
- +49.4%
- FY2018 revenue growth
- +21.0%
- FY2019 revenue growth
- +24.5%
- FY2020 revenue growth
- +3.9%
- FY2021 revenue growth
- +15.1%
- FY2022 revenue growth
- -5.7%
- FY2023 revenue growth
- +15.3%
- FY2024 revenue growth
- +5.9%
- FY2025 revenue growth
- +19.7%
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $17.3M | +11.7% |
| Q4 2025 | $16.6M | +21.8% |
| Q3 2025 | $17.2M | +37.9% |
| Q2 2025 | $17.2M | +14.2% |
| Q1 2025 | $15.5M | +7.5% |
| Q4 2024 | $13.7M | -0.8% |
| Q3 2024 | $12.5M | -6.8% |
| Q2 2024 | $15.1M | +6.6% |
Multi-year avg. share of annual revenue by fiscal quarter
Revenue Breakdown (FY 2025)
XGN's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
XGN Revenue Analysis (2012–2025)
Current Revenue & Growth
As of June 24, 2026, Exagen Inc. (XGN) generated trailing twelve-month (TTM) revenue of $68.4 million, reflecting strong growth of +11.7% year-over-year. The most recent quarter (Q1 2026) recorded $17.3 million in revenue, up 4.1% sequentially.
Historical Growth Trajectory
XGN's 5-year compound annual growth rate (CAGR) stands at +9.7%, indicating steady revenue expansion. The 3-year CAGR of +13.5% exceeds the 5-year average, indicating an acceleration in the most recent period. Exagen Inc.'s highest annual revenue of $66.6 million was recorded in 2025, an all-time high.
Revenue by Segment
XGN's revenue is primarily driven by Reportable Segment (100%). With over half of revenue concentrated in Reportable Segment, the company has a focused business model while developing other growth vectors.
Peer Comparison
Compared to Healthcare sector peers — including CDNA (+19.2% YoY), NTRA (+36.6% YoY), and VCYT (+16.9% YoY) — XGN has underperformed the peer group in revenue growth. Compare XGN vs CDNA →
XGN Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| XGNCurrent | $68M | +11.7% | +9.7% | -21.1% | |
 CDNA | $380M | +19.2% | +14.6% | -5.5% | |
 NTRA | $2.3B | +36.6% | +42.6% | -13.4% | |
 VCYT | $517M | +16.9% | +34.5% | 14.3% | |
 CSTL | $344M | -2.1% | +40.6% | -12.4% | |
 MYGN | $825M | -0.3% | +8.2% | -8.2% |
XGN Historical Revenue Data (2012–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $66.6M | +19.7% | $38.8M | 58.3% | $-14,070,000 | -21.1% |
| 2024 | $55.6M | +5.9% | $33.1M | 59.5% | $-13,636,000 | -24.5% |
| 2023 | $52.5M | +15.3% | $29.5M | 56.1% | $-22,837,000 | -43.5% |
| 2022 | $45.6M | -5.7% | $21.3M | 46.9% | $-46,051,000 | -101.1% |
| 2021 | $48.3M | +15.1% | $27.7M | 57.4% | $-24,067,000 | -49.8% |
| 2020 | $42.0M | +3.9% | $25.4M | 60.6% | $-15,185,000 | -36.2% |
| 2019 | $40.4M | +24.5% | $21.6M | 53.4% | $-9,299,000 | -23.0% |
| 2018 | $32.4M | +21.0% | $17.1M | 52.6% | $-4,880,000 | -15.0% |
| 2017 | $26.8M | +49.4% | $12.7M | 47.3% | $-7,836,000 | -29.2% |
| 2015 | $17.9M | +53.9% | $8.4M | 46.9% | $-10,388,000 | -57.9% |
| 2014 | $11.7M | +281.8% | $4.8M | 41.0% | $-11,556,000 | -99.1% |
| 2013 | $3.1M | +229.9% | $225K | 7.4% | $-9,144,000 | -299.3% |
| 2012 | $926K | - | $-1,048,000 | -113.2% | $-6,826,000 | -737.1% |
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
14+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
XGN — Frequently Asked Questions
Quick answers to the most common questions about buying XGN stock.
Is XGN's revenue growth accelerating or slowing?
XGN revenue growth is holding steady at +11.7% year-over-year. TTM revenue is $68M. The current growth rate closely tracks the 5-year CAGR of +9.7%, signalling consistent execution.
What is XGN's revenue history from 2012 to 2026?
Exagen Inc. (XGN) revenue history spans 2012 to 2026. TTM revenue as of 2026 is $68M, growing at +11.7% YoY. The 5-year CAGR is +9.7%. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is XGN's long-term revenue growth rate (CAGR)?
Exagen Inc.'s 5-year revenue CAGR of +9.7% reflects the sustained nature of its business expansion. As of 2026, the current YoY growth rate of +11.7% is in line with this long-term average. CAGR is the most reliable measure of sustained revenue momentum for XGN.
Why does XGN's quarterly revenue fluctuate?
XGN quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Exagen Inc.'s revenue data from 2012 to 2026 shows full historical quarterly detail on this page.
How is XGN's revenue distributed by segment?
XGN reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does XGN's revenue compare to industry peers?
Exagen Inc. (XGN) with TTM revenue of $68M and +11.7% YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.